Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis

Drugs

Volumn 63, Issue 17, 2003, Pages 1799-1812

  Pande, Hemant ^a   Thuluvath, Paul J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFECTIVE AGENT; CALCITONIN; CEFTAZIDIME; CORTICOSTEROID DERIVATIVE; GABEXATE MESILATE; GLUCAGON; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; LOXIGLUMIDE; NIFEDIPINE; OCTREOTIDE; PROTEIN INHIBITOR; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE PANCREATITIS; ALLERGIC REACTION; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEADACHE; HUMAN; INCIDENCE; INHIBITION KINETICS; META ANALYSIS; NAUSEA; POSTOPERATIVE PERIOD; REVIEW; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CLINICAL TRIALS; HUMANS; PANCREATITIS; RISK FACTORS;

BACTERIA (MICROORGANISMS); UNIDENTIFIED AGENTS;

EID: 0041331410     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363170-00003     Document Type: Review

References (74)

1. Guelrud M. Endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin N Am 2001 Oct; 11 (4): 585-601
2. Devereaux CE, Binmoeller KF. Endoscopic retrograde cholangiopancreatography in the next millennium. Gastrointest Endosc Clin N Am 2000 Jan; 10 (1): 117-33
3. Aliperti G. Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin N Am 1996 Apr; 6 (2): 379-407
4. Freeman ML. Procedure-specific outcomes assessment for endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin N Am 1999 Oct; 9 (4): 639-47
5. Mergener K, Baillie J. Acute pancreatitis. BMJ 1998 Jan 3; 316 (7124): 44-8
6. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med 1994 Apr 28; 330 (17): 1198-210
7. Calleja GA, Barkin JS. Acute pancreatitis. Med Clin North Am 1993 Sep; 77 (5): 1037-56
8. Skude G, Wehlin L, Maruyama T, et al. Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography. Gut 1976 Feb; 17 (2): 127-32
9. Fjosne U, Waldum HL, Romslo I, et al. Amylase, pancreatic isoamylase and lipase in serum before and after endoscopic pancreatography. Acta Med Scand 1986; 219 (3): 301-4
10. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-18
11. Sherman S, Ruffolo TA, Hawes RH, et al. Complications of endoscopic sphincterotomy: a prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991 Oct; 101 (4): 1068-75
12. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001 Oct; 54 (4): 425-34
13. Akashi R, Kiyozumi T, Tanaka T, et al. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002 Jan; 55 (1): 50-4
14. Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002; 34: 280-5
15. Lerch MM, Gorelick FS. Early trypsinogen activation in acute pancreatitis. Med Clin North Am 2000 May; 84 (3): 549-63
16. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000 Sep; 106 (6): 773-81
17. Gukovsky I, Gukovskaya AS, Blinman TA, et al. Early NF-kappa B activation is associated with hormone-induced pancreatitis. Am J Physiol 1998; 275: G1402-14
18. Beger HG, Gansauge F, Mayer JM. The role of immunocytes in acute and chronic pancreatitis: when friends turn into enemies. Gastroenterology 2000 Mar; 118 (3): 626-9
19. Mayer J, Rau B, Gansauge F, et al. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000 Oct; 47 (4): 546-52
20. Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg 1995 Jan; 82 (1): 6-13
21. Giroir BP. Pancreatitis, cytokines, and SIRS: deja vu all over again? Crit Care Med 1999 Apr; 27 (4): 680-1
22. Giroir BP. Mediators of septic shock: new approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 1993 May; 21 (5): 780-9
23. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998 Jan; 175 (1): 76-83
24. Denham W, Norman J. The potential role of therapeutic cytokine manipulation in acute pancreatitis. Surg Clin North Am 1999 Aug; 79 (4): 767-81
25. Curtis LD. Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Adv Exp Med Biol 1996; 416: 361-3
26. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995 Oct; 82 (10): 1414-20
27. Frossard JL, Saluja A, Bhagat L, et al. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 1999 Mar; 116 (3): 694-701
28. Inoue S, Nakao A, Kishimoto W, et al. Anti-neutrophil antibody attenuates the severity of acute lung injury in rats with experimental acute pancreatitis. Arch Surg 1995 Jan; 130 (1): 93-8
29. Cook IW, Karakozis S, Kim D, et al. Interleukin-10 attenuates proinflammatory cytokine production and improves survival in lethal pancreatitis. Am Surg 2001 Mar; 67 (3): 237-41
30. Van Laethem JL, Eskinazi R, Louis H, et al. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut 1998 Sep; 43 (3): 408-13
31. Bhatia M, Saluja AK, Hofbauer B, et al. Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A 1998 Apr 14; 95 (8): 4760-5
32. Bhatia M, Saluja AK, Singh VP, et al. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 2001 May; 280 (5): G974-8
33. Messmann H, Vogt W, Holstege A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997 Jan; 40 (1): 80-5
34. Messmann H, Vogt W, Falk W, et al. Interleukins and their antagonists but not TNF and its receptors are released in post-ERP pancreatitis. Eur J Gastroenterol Hepatol 1998 Jul; 10 (7): 611-7
35. Haber GB. Prevention of post-ERCP pancreatitis. Gastrointest Endosc 2000 Jan; 51 (1): 100-3
36. de Herder WW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002 Jan 1; 14 (1): 53-7
37. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999 May 1; 49 (5): 593-8
38. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000 Jan 1; 51 (1): 1-7
39. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-95
40. Tulassay Z, Dobronte Z, Pronai L, et al. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998 Nov; 12 (11): 1109-12
41. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001 Jul 1; 15 (7): 965-72
42. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002 Apr 1; 55 (4): 470-5
43. Hirano T, Manabe T, Tobe T. Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein. J Gastroenterol Hepatol 1991 May-Jun; 6 (3): 260-4
44. Ristkari SK, Ramo OJ, Kiviniemi H, et al. The effect of gabexate mesilate on the outcome of acute hemorrhagic pancreatitis in pigs. Res Exp Med (Berl) 1989; 189 (1): 1-8
45. Pederzoli P, Cavallini G, Falconi M, et al. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.): a prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993 Oct; 14 (2): 117-24
46. Di Francesco V, Mariani A, Angelini G, et al. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci 2002 Apr; 47 (4): 741-5
47. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. N Engl J Med 1996 Sep 26; 335 (13): 919-23
48. Ziebert JJ, Bjorkman DJ. Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success? Am J Gastroenterol 1997 Jun 1; 92 (6): 1067-8
49. Deviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001 Feb; 120 (2): 498-505
50. Dumot JA, Conwell DL, Zuccaro Jr G, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001 Jul; 96 (7): 2098-102
51. Staritz M, Poralla T, Ewe K, et al. Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut 1985 Feb; 26 (2): 194-7
52. Luman W, Pryde A, Heading RC, et al. Topical glyceryl trinitrate relaxes the sphincter of Oddi. Gut 1997 Apr; 40 (4): 541-3
53. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001 Sep; 88 (9): 1178-82
54. Imahori SC, Studley JG, Schenk Jr WG. Experimental acute pancreatitis in dogs and effects of steroids: a light and electron microscopic study with reference to pathogenesis. Pathol Res Pract 1984 May; 178 (5): 483-90
55. Studley JG, Schenk Jr WG. Pathophysiology of acute pancreatitis: evaluation of the effect and mode of action of steroids in experimental pancreatitis in dogs. Am J Surg 1982 Jun; 143 (6): 761-4
56. Lium B, Ruud TE, Pillgram-Larsen J, et al. Sodium taurocholate-induced acute pancreatitis in pigs: pathomorphological studies of the pancreas in untreated animals and animals pretreated with high doses of corticosteroids or protease inhibitors. Acta Pathol Microbiol Immunol Scand [A] 1987 Nov; 95 (6): 377-82
57. Weiner GR, Geenen JE, Hogan WJ, et al. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995 Dec; 42 (6): 579-83
58. De Palma GD, Catanzano C. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999 Apr; 94 (4): 982-5
59. Schmid SW, Uhl W, Friess H, et al. The role of infection in acute pancreatitis. Gut 1999 Aug; 45 (2): 311-6
60. Hayashi J, Kawarada Y, Isaji S, et al. Therapeutic effects of continuous intraarterial antibiotic infusion in preventing pancreatic infection in experimental acute necrotizing pancreatitis. Pancreas 1996 Aug; 13 (2): 184-92
61. Mithofer K, Fernandez-del Castillo C, et al. Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Gastroenterology 1996 Jan; 110 (1): 232-40
62. Raty S, Sand F, Pulkkinen M, et al. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001 Jul-Aug; 5 (4): 339-45
63. Gabryelewicz A, Kosidlo S, Prokopowicz J, et al. Does heparin modify protease-antiprotease balance in acute experimental pancreatitis in rats. Hepatogastroenterology 1986 Apr; 33 (2): 79-82
64. Dobosz M, Wajda Z, Hac S, et al. Nitric oxide, heparin and procaine treatment in experimental ceruleine-induced acute pancreatitis in rats. Arch Immunol Ther Exp (Warsz) 1999; 47 (3): 155-60
65. Rabenstein T, Roggenbuck S, Framke B, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002 Apr; 55 (4): 476-83
66. Guelrud M, Mendoza S, Rossiter G, et al. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 1988 Oct; 95 (4): 1050-5
67. Khuroo MS, Zargar SA, Yattoo GN. Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial. Br J Clin Pharmacol 1992 May; 33 (5): 477-85
68. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54 (2): 105-11
69. Odes HS, Novis BN, Barbezat GO, et al. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977; 16 (1-2): 180-4
70. Silvis SE, Vennes JA. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 1975 May; 21 (4): 162-3
71. Budzynska A, Marek T, Nowak A, et al. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001 Sep; 33 (9): 766-72
72. Satake K, Kimura K, Saito T. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Digestion 1999; 60 Suppl. 1: 64-8
73. Shiratori K, Takeuchi T, Satake K, et al. Clinical evaluation of oral administration of a cholecystokinin-a-receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Pancreas 2002 Jul; 25 (1): E1-5
74. Ochi K, Harada H, Satake K. Clinical evaluation of cholecystokinin-a-receptor antagonist (loxiglumide) for the treatment of acute pancreatitis: a preliminary clinical trial. Study Group of loxiglumide in Japan. Digestion 1999; 60 Suppl. 1: 81-5